OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES

• US 20170119885A1
• Filed: 04/28/2015
• Published: 05/04/2017
• Est. Priority Date: 04/28/2014
• Status: Abandoned Application

• Current Assignee: Hampton Technologies, Inc.
• Original Assignee: Hampton Technologies, Inc.
• Inventors: Ellis, Edward J., Ellis, Jeanne Y.
• Application Number:
  US15/306,329
• Publication Number:
  US 20170119885A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/04 Artificial tears; Irrigation solutions
• CPC Class Codes: C11D 1/62 Quaternary ammonium compounds
• CPC Class Codes: C11D 3/0078 Compositions for cleaning contact lenses, spectacles or lenses

Abstract

Ophthalmic solutions are provided for use as tear substitutes and contact lens solutions. These solutions contain a cationic polymeric surfactant that has an affinity for the surface of the eye or a contact lens. Also disclosed are ophthalmic solutions containing a combination of the cationic polymeric surfactant and a water soluble anionic polymer which forms a complex in aqueous solution. The complex has an affinity for the surface of the eye or contact lens. In this manner, the present solutions provide improved duration of comfort to the user. The present compositions are also useful as carriers for ophthalmic drugs.

Claims

1. An ophthalmic composition comprising:

a cationic polymeric surfactant derived from a polysaccharide, wherein the cationic polymeric surfactant is represented by the overall structural formula;

2. The ophthalmic composition of claim 1, wherein the composition is in the form of a solution, gel, ointment or dispersion that is suitable for instilling into an eye.

3. The ophthalmic composition of claim 1, wherein the cationic polymeric surfactant is present in the amount of from about 0.01 to about 3.0 weight percent.

4. The ophthalmic composition of claim 1, wherein the cationic polymeric surfactant is derived from cellulose.

6. The ophthalmic composition of claim 1, further comprising at least one of tonicity adjusting agents, preservatives and disinfectants.

7. The ophthalmic composition of claim 1, wherein the cationic polymeric surfactant is Polyquaternium-24 (Cas Number 98616-25-2) or Polyquaternium-67.

8. The ophthalmic composition of claim 1, further comprising an anionic polymer comprising one of sodium hyaluronate and a potassium hyaluronate, wherein the cationic polymeric surfactant and the anionic polymer form a complex.

9. The ophthalmic composition of claim 8, wherein the cationic polymeric surfactant is present in the amount of from about 0.01 to about 3.0 weight percent and the sodium hyaluronate or potassium hyaluronate is present in the amount of from about 0.01 to about 5.0 percent by weight.

10. The ophthalmic composition of claim 1, wherein the composition comprises and aqueous solution and the cationic polymeric surfactant comprises a hydrophobic cationic cellulose.

11. The ophthalmic composition of claim 1, further comprising an ophthalmic drug.

12. The ophthalmic composition of claim 8, wherein the cationic polymeric surfactant comprises a hydrophobic cationic cellulose and the anionic polymer comprises sodium hyaluronate and a ratio between the weight percent of the hydrophobic cationic cellulose compared to the sodium hyaluronate is between 1/10 and 10/1.

13. The ophthalmic composition of claim 12, wherein the buffering agent comprises a mixture of sodium borate and boric acid, and the demulcent comprises hydroxyethyl cellulose and the composition further comprises a tonicity agent in the form of sodium chloride.

14. The ophthalmic composition of claim 8, wherein the cationic polymeric surfactant comprises a hydrophobic cationic cellulose and the anionic polymer comprises sodium hyaluronate and the buffering agent comprises a mixture of sodium borate and boric acid and the composition further comprises glycerin, and a preservative component comprising an oxychloro complex.

15. A method for treating at least one condition selected from the group consisting of dry eye syndrome, keratitis sicca, xerophthalmia, keratoconjunctivitis sicca, ocular discomfort, rhinological allergic complications, Sjogren'"'"'s syndrome, chronic low blink rate (VDT syndrome), recovery from LASIK vision correction surgery, and Stevens Johnson syndrome comprising the step of administering a solution that contains the composition of claim 1.

16. The method of claim 15, wherein the cationic polymeric surfactant is present in the amount of from about 0.01 to about 3.0 weight percent.

17. The method of claim 15, further comprising at least one of preservatives and disinfectants.

18. The method of claim 15, wherein the cationic polymeric surfactant is Polyquaternium-24 (Cas Number 98616-25-2) or Polyquaternium-67.

19. The method of claim 15, wherein the composition further includes an anionic polymer that complexes with the cationic polymeric surfactant, the anionic polymer comprising one of sodium hyaluronate and potassium hyaluronate.

20. The method of claim 19, wherein the cationic polymeric surfactant is present in the amount of from about 0.01 to about 3.0 weight percent and the sodium hyaluronate or potassium hyaluronate is present in the amount of from about 0.01 to about 5.0 percent by weight.

21. The method of claim 15, wherein the composition comprises an aqueous solution and the cationic polymeric surfactant comprises a hydrophobic cationic cellulose.

22. The method of claim 15, further comprising an ophthalmic drug.

23. The method of claim 19, wherein the cationic polymeric surfactant comprises a hydrophobic cationic cellulose and the anionic polymer comprises sodium hyaluronate and a ratio between the weight percent of the hydrophobic cationic cellulose compared to the sodium hyaluronate is between 1/10 and 10/1.

25. The ophthalmic composition of claim 1, wherein the demulcent is selected from the group consisting of:

polyvinyl alcohol, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, polyethylene oxide, polyethylene glycol, polyethyleneoxide, guar, carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose, carboxyethylhydroxyethyl cellulose, carboxymethyl guar, carboxymethylhydroxypropyl guar, cellulose phosphate, chondoitin sulfate, N-carboxymethyl chitosan, alginates, sodium or potassium salts, xanthan, hyaluronic acid, glycomacropeptide, carboxy vinyl polymer, and carbomer.

26. The ophthalmic composition of claim 1, wherein the buffering agent comprises a mixture of sodium borate and boric acid.

5. (canceled)

24. (canceled)

27. A method for forming an ophthalmic composition comprising the steps of:

adding a cationic polymeric surfactant to an aqueous solution including a demulcent and a buffering agent to form the ophthalmic composition, wherein the cationic polymeric surfactant being derived from a polysaccharide, wherein the cationic polymeric surfactant is represented by the overall structural formula;

28. The method of claim 27, wherein the demulcent is selected from the group consisting of:

polyvinyl alcohol, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, polyethylene oxide, polyethylene glycol, polyethyleneoxide, guar, carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose, carboxyethylhydroxyethyl cellulose, carboxymethyl guar, carboxymethylhydroxypropyl guar, cellulose phosphate, chondoitin sulfate, N-carboxymethyl chitosan, alginates, sodium or potassium salts, xanthan, hyaluronic acid, glycomacropeptide, carboxy vinyl polymer, and carbomer.

29. The method of claim 27, wherein the buffering agent comprises a mixture of sodium borate and boric acid.